Merck sentencing concludes long-running US Vioxx probe
This article was originally published in Scrip
Executive Summary
Merck was ordered to pay $321.6 million in criminal fines stemming from earlier charges it illegally promoted and marketed its its cyclooxygenase-2-selective nonsteroidal anti-inflammatory drug Vioxx (rofecoxib) under a larger settlement it agreed to late last year, US prosecutors disclosed on 19 April, bringing a long-running investigation into the firm to a close.